We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

IDS LIMITED

Immunodiagnostic Systems Holdings PLC (IDS) develops, manufactures, and markets immunoassays and automated immunoanal... read more Featured Products: More products

Download Mobile App





IDS Exhibits Next Generation Automated Immunoanalyzer IDS-i10 at MEDICA 2019

By LabMedica International staff writers
Posted on 18 Nov 2019
Immunodiagnostic Systems {(IDS) Tyne & Wear, UK} exhibited its next generation automated immunoanalyser, the IDS-i10, at the 2019 edition of MEDICA, the world's largest trade fair for medical technology, held from 18 to 21 November in Düsseldorf, Germany. More...
At MEDICA 2019, IDS also discussed its unique panel of automated and manual assays, with experts available onsite to answer the visitors’ queries.

More than 5,000 exhibitors from 70 countries presented their newest products and ideas at MEDICA which drew 120,000 trade visitors from over 170 countries. In-patient and out-patient medicine, medical technology, diagnostic systems and electromedical and laboratory equipment were all on display throughout the event. The exhibition welcomed business, research and politics leaders, sharing their insights and findings with thousands of international experts. The immersive program also included a series of forums and conferences.

IDS develops, manufactures, and markets innovative immunoassays in both automated and manual formats. The company’s portfolio includes specialty testing solutions in the fields of Endocrinology, Autoimmunity, Allergy and Infectious Disease. The IDS-i10 next generation immunoanalyzer comes with faster testing capability and the capacity to connect to laboratory track systems, which can help medical professionals perform automated immunoassays more efficiently than ever. The chemiluminescence-based technology platform is entirely automated and offers continuous loading, as well as random access analysis.

Related Links:
Immunodiagnostic Systems


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Repetitive Pipette
VWR® Stepper Pro
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.